BTG
LIVE

Serial Number

86370062

Owner

BTG International Limited

Attorney

Jonathan A. Hyman

Filing Date

Aug 18, 2014

Add to watchlist:

No watchlists yet
View on USPTO

BTG Trademark

Serial Number: 86370062 • Registration: 4962342

BTG is a trademark filed by BTG International Limited on August 18, 2014. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

BTG International Limited (35 trademarks)

5 Fleet Place
London EC4M 7RD , GB

Entity Type: 11

PROTHERICS MEDICINES DEVELOPMENT LIMITED

10 Paternoster Row
London EC4M7EJ , GB

Entity Type: 24

Trademark Details

Filing Date

August 18, 2014

Registration Date

May 24, 2016

Published for Opposition

July 7, 2015

Goods & Services

Pharmaceutical, medicinal and veterinary preparations and substances, namely, vaccines, antitoxic sera, pharmaceutical preparations for the treatment of cancer, pharmaceutical preparations and substances for the treatment of thrombosis, embolisms, inflammation, and autoimmune disease, pharmaceutical preparations for the treatment of envenomation by snakes, veterinary preparations for the treatment of envenomation by snakes, and dietetic foods adapted for medical use, namely, food supplements containing vitamins, minerals, trace elements, oils and fats, either apart or in combinations thereof for use in the treatment of cardiovascular issues, vascular issues or cancer, liquid medical sealants, and liquid adhesives for use in surgical and clinical procedure; pharmaceutical and medicinal preparations and substances, namely, vaccines and vaccine adjuvants, proteins, peptides, sera containing polyclonal antibodies and fragments thereof and polyclonal antibodies and fragments derived therefrom all for use in treating snake envenomation, overdose of toxic substances, and sepsis; drug delivery agents, namely, preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances; preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations and substances for use in the circulatory system; pharmaceutical preparations and substances for embolisation; pharmaceutical preparations and substances for embolisation of tumours and arteriovenous malformations (AVMs); pharmaceutical preparations and substances for use in the circulatory system for the treatment of tumours and AVMs; adjuvants for medicinal purposes, vaccine adjuvants and vaccine preparations containing adjuvant; chemical reagents for medical and veterinary purposes for the treatment of envenomation by snakes; chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes; chemico-pharmaceutical preparations for the treatment of envenomation by snakes; chemical preparations for medical and pharmaceutical purposes for the treatment of envenomation by snakes; medicines for the treatment of envenomation by snakes; pharmaceutical and veterinary preparations for the treatment of digoxin, digitalis and other cardio-active glycoside toxicity; pharmaceutical and veterinary preparations for the treatment of pre-eclampsia; chemical reagents for medical and veterinary therapeutic and diagnostic purposes; chemico-pharmaceutical preparations for use in the treatment of digoxin, digitalis and other cardio-active glycoside toxicity, and for use in the treatment of pre-eclampsia; chemical preparations for medical and pharmaceutical purposes and medicines for use in the treatment of digoxin, digitalis and other cardio-active glycoside toxicity and for use in the treatment of pre-eclampsia; transarterial chemoembolisation pharmaceutical preparations, vaccines and sera; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, therapeutic agents for delivery of radioactive materials to target sites within the body for the treatment of cancer; irradiated and radioactive microspheres used for in vivo therapeutic medical purposes, namely, beads in the nature of microscopic glass beads impregnated with radioactive pharmaceutical preparations for treatment of cancerous tumors; radiotherapy substances for medical purposes, namely, radioactive pharmaceutical preparations for medical purposes for the treatment of cancer; radiopharmaceuticals, namely, radiopharmaceuticals for the treatment of cancer and radiopharmaceutical preparations for use in nuclear medicine; therapeutic agents for delivery of radioactive material to target sites within the body; beads, including microscopic radioactive beads featuring pharmaceutical preparations for treatment of cancerous tumours; beads, including microscopic glass beads, impregnated with radioactive pharmaceutical preparations and consisting of radioactive material for treatment of cancerous tumours; radioactive glass beads impregnated with pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use with ultrasound waves to enhance drug delivery and medically activate drugs; pharmaceutical preparations in the form of foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams for use in producing foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams and for use in preparing foams, for sclerotherapy, phlebology, angiology and proctology, namely, for the treatment of oesophageal varices, hydroceles, in sterilisation treatment and for treatment of varicose veins, and arterio-venous malformations; pharmaceutical preparations containing methotrexate antidotes; pharmaceutical preparations containing 5-fluorouracil antidotes; pharmaceutical preparations for use in chemotherapy and for the treatment of autoimmune diseases; pharmaceutical preparations used for regulating toxicity levels of therapeutic agents; pharmaceutical preparations used for depleting concentrations of therapeutic agents

Surgical, medical and veterinary apparatus and instruments, namely, medical syringes, surgical and medical apparatus for producing and administering pharmaceutical foams, surgical and medical apparatus for producing foams for treatment of varicose veins, arterio-venous malformations, oesophageal varices and hydroceles, devices for intravenous administration of pharmaceutical foam, and diagnostic devices for grading the severity of venous conditions, snake envenomation and toxic drugs overdose; surgical, medical and veterinary apparatus and instruments, namely, medical devices for use in pulmonary and thoracic surgery and procedures, lung air trapping reduction coils, lung volume reduction devices, surgical implants comprising artificial material, surgical implants comprising artificial materials for restoring, maintaining and improving patient breathing and artificial surgical implants for restoring, maintaining and improving lung function, and catheters for deploying these; surgical, medical and veterinary apparatus and instruments, namely, medical device, apparatus and instruments for treating cancer; drug delivery embolisation apparatus, instruments and systems; apparatus and instruments for use in the circulatory system, namely, catheters, injection syringes and sealed vials; medical apparatus and instruments for embolisation; surgical and medical apparatus and instruments, namely, catheters, injection syringes and sealed vial devices for dispensing microspheres during embolisation procedures in blood vessels and in the circulatory system; embolisation apparatus, instruments and systems comprising surgical and medical instruments for embolization, namely, embolic devices for use in treating cancer and tumors, embolic devices for treating arteriovenous malformations (AVMs) of the body, and embolic devices for use in treating tumors; drug delivery embolisation systems; drug delivery apparatus and instruments namely, a drug delivery system comprised of injection syringes and sealed vials; injection syringes for use with catheters; apparatus and instruments for use in the circulatory system, namely, catheters, injection syringes and sealed vials for dispensing microspheres during embolisation procedures in blood vessels and in the circulatory system; medical apparatus and instruments for embolization, namely, medical devices in the nature of embolic microspheres for embolization; surgical and medical apparatus and instruments for embolisation, namely, embolisation apparatus, instruments and systems comprising microspheres and injection syringes for use in blood vessels and the circulatory system to carry out embolisation; radiotherapy apparatus; surgical and medical apparatus and instruments for delivery of radiopharmaceuticals and radioactive material to target sites within the body; beads, namely, microscopic radioactive glass beads administered surgically for treatment of cancerous tumours; radioactive beads, namely, radioactive glass beads administered for treatment of cancerous tumours; surgical and medical apparatus and instruments for use in the circulatory system; medical devices in the nature of drug delivery systems which use ultrasound to enhance drug delivery and medically activate drugs; catheters for delivery of drugs and fluids sold together as a unit with controllers and power units for infusion catheters; ultrasonic drug delivery and drug activation apparatus sold together as a unit with controllers and power units therefor; needles for medical use, namely, cannula needles; medical tubing for sclerotherapy; medical tubing for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for producing and administering foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for producing and administering sclerosing foams for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; surgical and medical apparatus for producing and administering foams for use in sclerotherapy, phlebology, angiology and proctology; syringes for producing and administering foams for use in sclerotherapy, phlebology, angiology and proctology; surgical and medical apparatus for administering and producing foams for use in sterilisation treatment; surgical and medical apparatus for use in treatment of varicose veins, arterio-venous malformations, oesophageal varices and hycroceles; syringes for use in treatment of varicose veins, arterio-venous malformations, oesophageal varices and hydroceles; devices for assessing the physical characteristics of such foams, namely, medical diagnostic apparatus for analyzing the efficacy of sclerotherapy foams for medical purposes; medical devices for intravenous administration of sclerosing foam for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; medical devices for monitoring the position and effect of sclerosing foam in the human body for the treatment of varicose veins, venous malformations, arterio-venous malformations, oesophageal varices and hydroceles; medical diagnostic apparatus for diagnosing all the above medical conditions, namely, varicose veins, arterio-venous malformations, oesophageal varices, spider veins hydroceles, cancer, tumors, and circulatory system conditions and pulmonary and thoracic conditions; compression bandages; component parts and fittings for all of the aforesaid goods; irradiated or radioactive microspheres used for in vivo therapeutic medical purposes, namely, implantable radiation therapy devices consisting of radioactive beads in the nature of microscopic radioactive beads for treatment of cancerous tumours; implantable radiation therapy devices consisting of radioactive beads and a bioabsorbable carrier assembly, namely, beads in the nature of microscopic radioactive beads for treatment of cancerous tumours and beads in the nature of radioactive microscopic glass beads for treatment of cancerous tumours; radioactive glass beads, namely, implantable radiation therapy devices consisting of radioactive beads and a bioabsorbable carrier assembly and implantable radiation therapy devices consisting of radioactive beads; radioactive glass beads, namely, implantable radiation therapy devices consisting of radioactive glass beads administered for treatment of cancerous tumours

Filing History

TEAS SECTION 8 & 9 RECEIVED
May 26, 2026 E89R
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
May 24, 2025 REM2
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 14, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 14, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 14, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 14, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 14, 2025 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jul 13, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 13, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 13, 2023 REAP
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Apr 11, 2023 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Apr 11, 2023 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 7, 2023 APRE
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 16, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 16, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 16, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 16, 2023 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 16, 2023 COAR
TEAS SECTION 8 & 15 RECEIVED
Sep 28, 2022 E815
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 12, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 12, 2022 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Apr 12, 2022 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 12, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 12, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 12, 2022 COAR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 30, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 30, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 30, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 30, 2021 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 30, 2021 COAR
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
May 24, 2021 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 22, 2021 ASGN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Aug 29, 2020 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Aug 29, 2020 TCCA
TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Aug 29, 2020 EWOR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Aug 29, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Aug 29, 2020 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Aug 29, 2020 COAR
REGISTERED-PRINCIPAL REGISTER
May 24, 2016 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Apr 14, 2016 DP1B
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 3, 2016 AITU
NOTICE OF ALLOWANCE CANCELLED
Feb 22, 2016 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Feb 22, 2016 D1BR
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 1, 2015 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 7, 2015 NPUB
PUBLISHED FOR OPPOSITION
Jul 7, 2015 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 17, 2015 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 1, 2015 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 1, 2015 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 28, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 27, 2015 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 27, 2015 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Apr 13, 2015 GPRN
PRIORITY ACTION E-MAILED
Apr 13, 2015 GPRA
PRIORITY ACTION WRITTEN
Apr 13, 2015 CPRA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 21, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 20, 2015 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 20, 2015 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 21, 2014 GNRN
NON-FINAL ACTION E-MAILED
Nov 21, 2014 GNRT
NON-FINAL ACTION WRITTEN
Nov 21, 2014 CNRT
ASSIGNED TO EXAMINER
Nov 14, 2014 DOCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 29, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 29, 2014 CRFA
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 29, 2014 NWOS
ASSIGNED TO LIE
Aug 22, 2014 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Aug 21, 2014 PARI
NEW APPLICATION ENTERED
Aug 21, 2014 NWAP